

Introducing the Science behind Targeted Treatments for non-small cell lung cancer and immunotherapy

Thursday 3rd September 2020

Event ID: 901

Introduction: Over the course of two mornings, experienced cancer educator, Dr Elaine Vickers, guides you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).

The first morning's focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.

The second morning is about cancer's relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.

As ever, Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Elaine's descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Format:

Each morning's content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video.

Audience:


This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer, and to junior doctors.

Cost: £50 per delegate

Register: www.royalmarsden.nhs.uk/studydays

Get in touch:  Conferenceteam@rmh.nhs.uk

Follow us:

 020 7808 2921



Please note that the content will be available for 30 days after the event online

Topic 2:

Introducing the science behind immunotherapy for non-small cell lung cancer

Description:

The focus of this morning is on cancer's relationship with the immune system, and how this knowledge is being used to improve the outlook of people with NSCLC using checkpoint inhibitor-based immunotherapy. Elaine will describe checkpoint inhibitors' mechanism of action. And, by drawing on the knowledge gained through many clinical trials, she will also describe their strengths and limitations.

Session 1—cancer's relationship with the immune system

- A brief introduction to the Immune system
- How cancer's relationship with the immune system changes over time
- How the immune system can recognise and react to the presence of cancer in the body
- Mechanisms of Immune-evasion by cancer cells

Live Q&A

Session 2—Introduction to checkpoint inhibitors

- Introduction to T cells and checkpoint proteins
- Mechanism of action of checkpoint inhibitors
- Spot the difference: CTLA-4 and PD-1/P-L1 targeted checkpoint inhibitors
- Examples of results from clinical trials

Live Q&A

Session 3—making the most of checkpoint inhibitor immunotherapy

- A few lessons learned from clinical trials
- Why combine checkpoint inhibitors with chemotherapy, and why not
- Biomarkers of response and resistance to checkpoint inhibitors

Live Q&A

Trailer Video: Introducing Immunotherapy for Lung Cancer

Main Sponsors:



The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.